Free Trial
NASDAQ:CELU

Celularity Q4 2024 Earnings Report

Celularity logo
$2.96 -0.20 (-6.33%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$3.02 +0.06 (+1.86%)
As of 07/25/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celularity EPS Results

Actual EPS
-$0.59
Consensus EPS
-$1.50
Beat/Miss
Beat by +$0.91
One Year Ago EPS
N/A

Celularity Revenue Results

Actual Revenue
$18.13 million
Expected Revenue
$5.20 million
Beat/Miss
Beat by +$12.93 million
YoY Revenue Growth
N/A

Celularity Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Celularity's Q1 2025 earnings is scheduled for Wednesday, July 30, 2025, with a conference call scheduled at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Celularity Earnings Headlines

Celularity Inc. (CELU) Stock Price Today - WSJ
AI's Next Magnificent Seven
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

View Celularity Profile

More Earnings Resources from MarketBeat